Cover Image

In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach

Targeting epidermal growth factor receptor (EGFR) mutants is a promising strategy for treating non-small cell lung cancer (NSCLC). This study focused on the computational identification and characterization of potential EGFR mutant-selective inhibitors using pharmacophore design and validation by de...

Full description

Saved in:

Bibliographic Details
Main Authors:	Md Ali Asif Noor (Author), Md Mazedul Haq (Author), Md Arifur Rahman Chowdhury (Author), Hilal Tayara (Author), HyunJoo Shim (Author), Kil To Chong (Author)
Format:	Book
Published:	MDPI AG, 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019)

iPseU-CNN: Identifying RNA Pseudouridine Sites Using Convolutional Neural Networks
by: Muhammad Tahir, et al.
Published: (2019)

An Explainable Supervised Machine Learning Model for Predicting Respiratory Toxicity of Chemicals Using Optimal Molecular Descriptors
by: Keerthana Jaganathan, et al.
Published: (2022)

Identification of miRNA-Small Molecule Associations by Continuous Feature Representation Using Auto-Encoders
by: Ibrahim Abdelbaky, et al.
Published: (2021)

Drug Therapeutic-Use Class Prediction and Repurposing Using Graph Convolutional Networks
by: Mapopa Chipofya, et al.
Published: (2021)

Artificial Intelligence in Drug Metabolism and Excretion Prediction: Recent Advances, Challenges, and Future Perspectives
by: Thi Tuyet Van Tran, et al.
Published: (2023)

Targeting <i>BRAF</i> Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
by: Frank Aboubakar Nana, et al.
Published: (2021)

In silico analysis of wild-type and mutant KRAS
by: Frengki Frengki, et al.
Published: (2019)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
by: Pacini L, et al.
Published: (2021)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

Identifying potential ligand molecules EGFR mediated TNBC targeting the kinase domain-identification of customized drugs through in silico methods
by: Hima Vyshnavi, et al.
Published: (2023)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023)

Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma
by: Camila Robles-Oteiza, et al.
Published: (2021)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
by: Julie M. Janssen, et al.
Published: (2022)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
by: Panupong Mahalapbutr, et al.
Published: (2024)

Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
by: Fiona M. Healy, et al.
Published: (2024)

BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells
by: Duc-Hiep Bach, et al.
Published: (2018)

4-Aryl-N-phenylpyrimidin-2-amines targeting EGFR-tyrosine kinase attenuated EGFR-expressing cell lines
by: Lueacha Tabtimmai, et al.
Published: (2022)

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations
by: Wenliang Liu, et al.
Published: (2022)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021)

Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
by: Yuhan Zhang, et al.
Published: (2021)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFRWT, EGFRT790M, and EGFRL858R)
by: Mahmoud G. Abo Al-Hamd, et al.
Published: (2023)

Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
by: Francesca Foschi, et al.
Published: (2023)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016)

Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase
by: Mohd Rehan, et al.
Published: (2024)

Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
by: Xiaohan Zhou, et al.
Published: (2020)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
by: Cornelius Hempel, et al.
Published: (2017)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023)

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
by: Xiang M, et al.
Published: (2013)

Cytotoxic Desulfated Saponin from Holothuria atra Predicted to Have High Binding Affinity to the Oncogenic Kinase PAK1: A Combined In Vitro and In Silico Study
by: Md Shahinozzaman, et al.
Published: (2018)

Molecular modeling based approach, design synthesis and cytotoxic activity of 7-chloro-4-(2,5-dioxo-4-substitutedarylidine) piperazinoquinoline a hybrid pharmacophore, targeting EGFR, Tyrosine Kinase
by: Enayat Ibrahim Aly
Published: (2011)

Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
by: Fernando Franco, et al.
Published: (2017)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014)

Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents
by: Rania S.M. Ismail, et al.
Published: (2016)

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
by: Jing Zhu, et al.
Published: (2021)